Pharmacovigilance Study of Anticancer Drugs in a Tertiary Care Rural Hospital in Central India

Author:

Chakraborty Dipankar1ORCID,Kale Ranjana S2ORCID,Das Lakshman3ORCID,Das Mousumi1ORCID,Kirde Sonali2ORCID

Affiliation:

1. 1Department of Pharmacology, Agartala Government Medical College, Agartala, Tripura, India.

2. 2Department of Pharmacology, Mahatma Gandhi Institute of Medical Sciences, Sewagram, Wardha, Maharashtra. India.

3. 3Department of Pharmacology, Tripura Medical College and Dr BRAM Teaching Hospital, Hapania, Agartala, Tripura, India.

Abstract

The present study has been undertaken to evaluate the pattern of adverse drug reactions (ADRs) of intravenous anticancer (i.v.) drugs with their causality and severity in a tertiary health care set up. The study was an observational cross-sectional survey over a period of 18 months. The indoor patients who were diagnosed to have cancer and receiving i.v. anticancer drugs were included in the study. The details of the patients and ADRs were recorded at the time of visit or within one-month of occurrence of ADRs using case record form and ADR reporting form. A total of 374 patients on cancer chemotherapy were included in the study and ADR was seen in 293(78.34%) patients. Out of total 812 number of ADRs, most ADRs (51.60%) were G.I. system related, followed by skin and appendages related ADRs (23.88%). The association of females in developing haematological ADRs is statistically significant (p<0.05). Most common (19.80%) cause of ADRs was the use of combination of Cisplatin, Paclitaxel and 5 Fluorouracil. Most (90.02%) of the ADRs were categorized as ‘possible’ and the remaining (9.98%) as ‘probable/likely’. The maximum number of the ADRs were classified as ‘mild’(87.68%) followed by moderate (11.45%) and severe (0.86%). The mild reactions were more common as compare to moderate & severe category in G.I & haematology related ADRs (p<0.05).

Publisher

Oriental Scientific Publishing Company

Subject

Pharmacology

Reference27 articles.

1. 1. Tripathi KD. Adverse Drug Effects. In: Essentials of Medical Pharmacology. 2019. page 93

2. 2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse Drug Events in Hospitalized Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality. Surv Anesthesiol 1998;42(3):130–1.

3. 3. De A. Monitoring of Suspected Adverse Drug Reactions in Oncology Unit of an Urban Multispeciality Teaching Hospital. Int J Res Pharm Biomed Sci 2010;1(2):1–32.

4. 4. Sriram S, Ghasemi A, Ramasamy R, Devi M, Balasubramanian R, Ravi TK, et al. Prevalence of adverse drug reactions at a private tertiary care hospital in south India. J Res Med Sci 2011;16(1):16–25.

5. 5. Raut A, Diwan A, Patel C, Patel P, Pawar A. Incidence, severity and financial burden associated with adverse drug reactions in medicine inpatients. Asian J Pharm Clin Res 2011;4(SUPPL. 2):107–11.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3